Indivior PLC (INDV)
| Market Cap | 1.14B |
| Revenue (ttm) | 1.19B |
| Net Income (ttm) | -48.00M |
| Shares Out | 124.76M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | 8.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,484,689 |
| Open | 9.05 |
| Previous Close | 9.06 |
| Day's Range | 9.01 - 9.25 |
| 52-Week Range | 7.33 - 19.78 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 14.50 (+60.31%) |
| Earnings Date | Apr 24, 2025 |
About INDV
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for INDV stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 60.31% from the latest price.
News
Indivior Announces Further Changes to Board of Directors
RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director...
UK's Indivior appoints Joe Ciaffoni as CEO
British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
RICHMOND, Va. , Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer.
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va....
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.
UK's Indivior forecasts 17% decline in 2025 revenue
British drugmaker Indivior on Thursday projected a 17% decline in 2025 net revenue at the midpoint of its forecast range, partly hurt by sluggish sales of its film-form medication-assisted therapy for...
Indivior Announces FY and Q4 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024.
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes
RICHMOND, Va. , Feb. 12, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative...
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
RICHMOND, Va. , Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a lette...
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
RICHMOND, Va., Oct. 30, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Prevention Month, provides an update on key findings from the last year that demonstrate th...
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript
Indivior PLC (NASDAQ:INDV) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Christian Heidbreder - Chief Scientific Offi...
Indivior Announces Q3 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024.
Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025
Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors...
British drugmaker Indivior cuts 2024 revenue forecast, shares fall
British drugmaker Indivior on Thursday cut its 2024 net revenue forecast for the second time in three months, citing lower than expected revenues from its Sublocade treatment for opioid use disorder, ...
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW I...
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as...
INDV Deadline: Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of securities of Indivior ...
Indivior PLC Is Being Sued For Violating Securities Laws And Affected Investors Are Encouraged To Lend A Hand To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC ("Indivior" or ...
Indivior PLC Is Being Sued For Violating Securities Laws And Investors Are Urged To Assist The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC ("Indivior" or ...
Indivior PLC Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC ("Indivior" or ...
Investors in Indivior PLC Should Contact The Gross Law Firm Before October 1, 2024 to Discuss Your Rights – INDV
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Indivior PLC (NASDAQ: INDV).
Indivior PLC Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC ("Indivior" or ...
Top 3 Health Care Stocks That May Explode This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.